Ostarine, also known as MK-2866, is a research chemical classified as a SARM (selective androgen receptor module). This means to Select the Androgens for the Receptors and then Modulate, or modify, those specific ones.

Is it a logical conclusion that if it is possible to choose which receptors, then it is possible to control what is modified?

Originally intended as a possible treatment for some pretty serious diseases, Ostarine (MK-2866) shows promise in a way that other chemicals do not. While still in the trials phase, positive results from more than one thousand test subjects have brought a great deal of attention to this chemical.ostarine

The creation of Ostarine (MK-2866) came about after the search for a chemical without all of the nasty side effects of its non receptornon-receptor selective predecessors. Television advertises multiple products every day that have an unending list of side effects.

What if it were possible to essentially remove all of the bad side effects by only selecting the good and positive benefits? This is what Ostarine (MK-2866) was designed to do; it only selects the good receptors.

In activating these receptors, Ostarine (MK-2866) may allow a test subject to gain muscle, around seven pounds of it, instead of losing it. An unintentional positive is it may also improve mineral density in bone.

According to scientific research studies based on vitro test subjects, Diseases diseases that this would be potentially helpful for include cachexia, sarcopenia, and some forms of muscular dystrophy.

It is not yet known if this would be significant enough to warrant distribution for other treatments that are not considered related to the muscles, including breast cancer and urinary incontinence.

The first, cachexia, is defined as a weakness and wasting of the body due to severe chronic illness. It comes from the Greek kakos, meaning bad, and hexis, meaning condition. Sounding similar to anorexia, which is the result of severely reduced caloric intake, cachexia shares the same extreme loss of weight through loss of muscle.

However, the patient cannot be fed intravenously or simply encouraged to eat more. Adding calories does not help.

More than three-quarters of vitro patients subjects with advanced cancer will develop cachexia, also called cancer anorexia cachexia syndrome, which does not respond to typical therapies. It is a metabolic disorder that millions suffer from, and is often the last stage and most difficult to visualize.

Sarcopenia, another form of losing muscle tissue, is seen as a natural part of the aging process. Around the age of 35, muscle mass will decrease and with it goes strength, flexibility, and normal functioning.

Posted in business